---
title: "107 Growth-stage Medtech Investors (Nov 2026)"
last_updated: "2026-11-07"
rows: "107"
free_rows: "25"
source: "SEC Form D filings and our own research"
canonical: "https://theinvestordatabase.com/lists/growth-medtech-investors/"
---

# 107 growth-stage medtech investors

We list 107 growth-stage medtech investors as of November 2026: 70 have an SEC filing on file and 37 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (14), New York (9) and Massachusetts (8).

- 107 investors
- 53 with a fund filing or dated deal in the last 12 months
- $150M median fund size on file (SEC Form D, 46 firms)
- 580 named decision-makers on file

## First 25 of 107 growth-stage medtech investors

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| Echo Health Ventures | Corporate VC | Durham, NC | Growth | Medtech, Healthtech | Portfolio news, Sep 2026 | $518M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/echo-health-ventures/ |
| JSTAR Capital | VC firm | Austin, TX | Growth | Medtech, Healthtech, AI, Fintech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/jstar-capital/ |
| Mercia Asset Management | Fund manager | Henley-in-Arden, United Kingdom | Seed, Series A, Growth | Medtech, Healthtech, Future of Work, AI | Portfolio news, Oct 2026 | £400M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/mercia/ |
| Transformation Capital | VC firm | Boston, MA | Growth | Medtech, Healthtech | New fund, Sep 2026 | $800M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/transformation-capital/ |
| Whiterock | Fund manager | Belfast, United Kingdom | Growth | Medtech, Media, Generalist, Climate Tech | Portfolio news, Oct 2026 | £255M (own site) | 2026-11-05 | https://theinvestordatabase.com/investors/whiterock-finance/ |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Medtech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/bgf/ |
| NewVale Capital | VC firm | Boulder, CO | Growth | Medtech, Biotech, Healthtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/newvale-capital/ |
| Town Hall Ventures | VC firm | New York, NY | Growth | Medtech, Healthtech, Impact | New deal, Sep 2026 | $400M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/town-hall-ventures/ |
| Quartus | VC firm | New York, NY | Growth | Medtech, AI, Healthtech, B2B | New fund, Sep 2026 | $150M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/quartus/ |
| Accelmed | VC firm | Aventura, FL | Growth | Medtech, Healthtech, Developer Tools, Biotech | Portfolio news, Apr 2026 | $401M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/accelmed/ |
| HLM Investment Partners | VC firm | Waltham, MA | Growth | Medtech, Healthtech | New fund, Aug 2026 | $61M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/hlm-investment-partners/ |
| Claritas Signal Partners | VC firm | Nashville, TN | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Media | New deal, Aug 2026 | $14M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/claritas-signal-partners/ |
| Lauxera Capital Partners | VC firm | Paris, France | Growth | Medtech, Healthtech | New fund, May 2026 | €800M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/lauxera-capital-partners/ |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Medtech, Healthtech, Biotech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/arcventis-health-partners/ |
| Parkwalk Advisors | SEIS/EIS fund | London, United Kingdom | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Industrial Tech | New fund, Sep 2026 | £500M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/parkwalk/ |
| Sana Capital | VC firm | New York, NY | Growth | Medtech, Healthtech | New fund, Apr 2026 | $100M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/sana-capital/ |
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Medtech, Healthtech, Biotech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/longitude-venture-partners/ |
| Sprig Equity | VC firm | Wilmette, IL | Growth, Late stage | Medtech, Healthtech | New fund, Aug 2026 | $34M (SEC Form D, 2023) | 2026-11-05 | https://theinvestordatabase.com/investors/sprig-equity/ |
| MVM Partners LLP | VC firm | Boston, MA | Growth | Medtech, Healthtech, Biotech | Portfolio news, Jun 2026 | $1.0B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/mvm-partners-llp/ |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Medtech, Healthtech, Biotech | Portfolio news, Oct 2026 | $2.8B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/hbm-partners-ag/ |
| Khosla Ventures | VC firm | Menlo Park, CA | Pre-seed, Seed, Series A, Growth | Medtech, AI, Consumer, B2B | New fund, Aug 2026 | $1.9B (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/khosla-ventures/ |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Medtech, Biotech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/andera-partners/ |
| Eckuity Capital | VC firm | New York, NY | Growth | Medtech, Healthtech, Biotech | New fund, Jun 2026 | $300M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/eckuity-capital/ |
| Star51 Capital | VC firm | New York, NY | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Robotics | New deal, Sep 2026 |  | 2026-11-04 | https://theinvestordatabase.com/investors/star51-capital/ |
| Sandbox Clinical Ventures | VC firm | Chicago, IL | Seed, Series A, Series B, Growth | Medtech, Insurtech, Healthtech, AI | New fund, Sep 2026 | $100M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/sandbox-clinical-ventures/ |

You are seeing 25 of 107. The full list adds 82 more investors and 580 named decision-makers.

Get all 107 investors and 580 named contacts, $49, one-time: https://theinvestordatabase.com/buy/list/growth-medtech-investors
This page: https://theinvestordatabase.com/lists/growth-medtech-investors/

## Method and limits
- Source: 70 of the 107 rows carry an SEC filing (Form D or Form ADV). All 107 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states medtech and medical devices as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 107 rows: stage 107, sector 107, fund size 82, website 107. In the paid file: named decision-makers on 98 rows, firm email on 51, LinkedIn page on 68, check size on 23.

## Questions
### How many growth-stage medtech investors are there?
We list 107 as of November 2026. 53 of the 107 have a fund filing or a dated deal in the last 12 months.

### Which growth-stage medtech investors raised a new fund in the last 12 months?
22 of the 107 have a fund filing dated in the last 12 months. The most recent on this list are IVP: Venture capital for the Exceptional (Oct 2026), NewVale Capital (Oct 2026) and Transformation Capital (Sep 2026).

### What is the typical fund size of growth-stage medtech investors?
The median fund size on file for this list is $150M, across the 46 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 61 do not disclose a size there.

### How do I contact growth-stage medtech investors?
The paid file holds 580 named decision-makers across 98 of these 107 and a firm email for 51. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.

### Where does the data on growth-stage medtech investors come from?
70 of the 107 rows have an SEC filing on file (Form D or Form ADV) and 37 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.